8-K filing — CYTOKINETICS INC (CYTK)
Filed: 2026-08-28 AccNo: 0001193125-26-372456 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Cytokinetics shares are trading lower. The company reported pivotal Phase 3 ACACIA‑HCM results showing aficamten met both dual primary endpoints, with significant improvements in patient quality‑of‑life scores and exercise capacity versus placebo.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 28, 2026, 5:31 PM
- Checked
- Aug 28, 2026, 5:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cytokinetics Announced The Primary Results From ACACIA-HCM (Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-obstructive HCM), The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Read original at benzingaCytokinetics Announces Primary Results From Phase 3 Trial Of Aficamten In Non-Obstructive Hypertrophic Cardiomyopathy To Be Presented August 28 At ESC Congress
Read original at benzinga